CD47: A new target in cardiovascular therapy

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 28, Issue 4, 2008, Pages 615-621

  Isenberg, Jeff S ^a   Roberts, David D ^a   Frazier, William A ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CD47; Ischemia; Nitric oxide; Platelet aggregation; Thrombospondin 1

Indexed keywords

CD47 ANTIGEN; INTEGRIN; NITRIC OXIDE; THROMBOSPONDIN 1;

ANTIGEN FUNCTION; BIOLOGY; CARDIOVASCULAR SYSTEM; DRUG EFFECT; HUMAN; IN VIVO STUDY; ISCHEMIA; NONHUMAN; PHYSIOLOGY; PRIORITY JOURNAL; REGULATORY MECHANISM; SHORT SURVEY; THROMBOCYTE; ANIMAL; BIOLOGICAL MODEL; CARDIOVASCULAR DISEASE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; IMMUNOLOGY; MOUSE; MOUSE MUTANT; PATHOPHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD47; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; HUMANS; MICE; MICE, KNOCKOUT; MODELS, BIOLOGICAL; MODELS, MOLECULAR; NITRIC OXIDE; SIGNAL TRANSDUCTION; THROMBOSPONDIN 1;

EID: 42249097748     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.107.158154     Document Type: Short Survey

References (95)

1. Brown EJ, Hopper L, Ho T, Gresham HD. Integrin associated protein: a 50-kD plasma membrane antigen physically and functionally associated with integrins. J Cell Biol. 1990;111:2785-2794.
2. 3-dependent ligand binding. J Cell Biol. 1993;123:485-496.
3. Reinhold MI, Lindberg FP, Plas D, Reynolds S, Peters MG, Brown EJ. In vivo expression of alternatively spliced forms of integrin associated protein (CD47). J Cell Sci. 1995;108:3419-3425.
4. Lindberg FP, Lublin DM, Telen MJ, Veile RA, Miller YE, Donis-Keller H, Brown EJ. Rh-related antigen CD47 is the signal-transducer integrin associated protein. J Biol Chem. 1994;269:1567-1570.
5. Gao A-G, FP Lindberg, MB Finn, SD Blystone, EJ Brown, Frazier WA. Integrin-associated protein is a receptor for the C-terminal domain of thrombospondin. J Biol Chem. 1996b;271:21-24.
6. van Beek EM, Cochrane F, Barclay AN, and van den Berg TK. Signal regulatory proteins in the immune system. J Immunol. 2005;175:7781-7787.
7. Babic I, Schallhorn A, Lindberg FP, Jirik FR. SHPS-1 induces aggregation of Ba/F3 pro-B cells via an interaction with CD47 [published erratum appears in J Immunol (2000) 164, 5532]. J Immunol. 2000;164:3652-3658.
8. Han X, Sterling H, Chen Y, Saginario C, Brown EJ, Frazier WA, Lindberg FP, Vignery A. CD47, a ligand for the macrophage fusion receptor, participates in macrophage multinucleation. J Biol Chem. 2000;275:37984-37992.
9. Jian P, Lagenaur CF, Narayanan V. Integrin-associated protein is a ligand for the P84 neural adhesion molecule. J Biol Chem. 1999;274:559-562.
10. Seiffert M, Cant C, Chen Z, Rappold I, Brugger W, Kanz L, Brown EJ, Ullrich A, Buhring HJ. Human signal-regulatory protein is expressed on normal, but not on subsets of leukemic myeloid cells and mediates cellular adhesion involving its counterreceptor CD47. Blood. 1999;94:3633-3643.
11. Demeure CE, Tanaka H, Mateo V, Rubio M, Delespesse G, Sarfati M. CD47 engagement inhibits cytokine production and maturation of human dendritic cells. J Immunol. 2000;164:2193-2199.
12. Ticchioni M, Raimondi V, Lamy L, Wijdenes J, Lindberg FP, Brown EJ, Bernard A. Integrin-associated protein (CD47/IAP) contributes to T cell arrest on inflammatory vascular endothelium under flow. Faseb J. 2001;15:341-350.
13. Brown EJ, Frazier WA. Integrin-associated protein (CD47) and its ligands. Trends Cell Biol. 2001;11:130-135.
14. Subramanian S, Boder ET, Discher DE. Phylogenetic divergence of CD47 interactions with human signal regulatory protein alpha reveals locus of species specificity. Implications for the binding site. J Biol Chem. 2007;282:1805-1818.
15. Baenziger NL, Brodie GN, Majerus PW. Isolation and properties of a thrombin-sensitive protein of human platelets. J Biol Chem. 1972;247:2723-2731.
16. Adams JC, Lawler J. The thrombospondins. Int J Biochem Cell Biol. 2004;36:961-968.
17. Varani J, Riser BL, Hughes LA, Carey TE, Fligiel SE, Dixit VM. Characterization of thrombospondin synthesis, secretion and cell surface expression by human tumor cells. Clin Exp Metastasis. 1989;7:265-276.
18. Reed MJ, Irueta-Arispe L, O'Brien ER, Truong T, Labell T, Bornstein P, Sage EH. Expression of thrombospondins by endothelial cells. Injury is correlated with TSP-1. Am J Pathol. 1995;147:1068-1080.
19. Hu CJ, Chen SD, Yang DI, Lin TN, Chen CM, Huang TH, Hsu CY. Promoter region methylation and reduced expression of thrombospondin-1 after oxygen-glucose deprivation in murine cerebral endothelial cells. J Cereb Blood Flow Metab. 2006;26:1519-1526.
20. LaBell TL, Byers PH. Sequence and characterization of the complete human thrombospondin 2 cDNA: potential regulatory role for the 3′ untranslated region. Genomics. 1993;17:225-229.
21. Lawler J, Sunday M, Thibert V, Duquette M, George EL, Rayburn H, Hynes RO. Thrombospondin-1 is required for normal murine pulmonary homeostatis and its absence causes pneumonia. J Clin Invest. 1998;101:982-992.
22. Kosfeld MD, Pavlopoulos TV, Frazier WA. Cell attachment activity of the carboxyl-terminal domain of human thrombospondin expressed in escherichia coli. J Biol Chem. 1991;266:24257-24259.
23. Kosfeld MD, Frazier WA. Identification of a new cell adhesion motif in two homologous peptides from the COOH-terminal cell binding domain of human thrombospondin. J Biol Chem. 1993;268:8808-8814.
24. Kosfeld MD, Frazier WA. Identification of active peptide sequences in the carboxyl-terminal cell binding domain of human thrombospondin-1. J Biol Chem. 1992;267:16230-16236.
25. Gao A-G, Frazier WA. Identification of a receptor candidate for the carboxyl-terminal cell binding domain of thrombospondins. J Biol Chem. 1994;269:29650-29657.
26. Gao A-G, Lindberg FP, Dimitry JM, Brown EJ, Frazier WA. Thrombospondin modulates αvβ3 function through integrin associated protein. J Cell Biol. 1996;135:533-544.
27. Frazier WA, Gao A-G, Dimitry J, Chung J, Lindberg FP, Brown EJ, Linder ME. The thrombospondin receptor integrin-associated protein (CD47) functionally couples to heterotrimeric Gi. J Biol Chem. 1999;274:8554-8560.
28. IIbβ3. J Biol Chem. 1997;272:14740-14746.
29. Chung J, Wang XQ, Lindberg FP, Frazier WA. Thrombospondin-1 acts via IAP/CD47 to synergize with collagen in alpha2beta1-mediated platelet activation. Blood. 1999;94:642-648.
30. Wang XQ, Frazier WA. The thrombospondin receptor CD47 (IAP) modulates and associates with alpha2 beta1 integrin in vascular smooth muscle cells. Mol Biol Cell. 1998;9:865-874.
31. Barazi HO, Li Z, Cashel JA, Krutzsch HC, Annis DS, Mosher DF, Roberts DD. Regulation of integrin function by CD47 ligands. J Biol Chem. 2002;277:42859-42866.
32. McDonald JF, Zheleznyak A, Frazier WA. Cholesterol-independent interactions with CD47 enhance αvβ3 avidity. J Biol Chem. 2004;279:17301-17311.
33. Lindberg FP, Bullard DC, Caver TE, Gresham HD, Beaudet AL, Brown EJ. Decreased resistance to bacterial infection and granulocyte defects in IAP-deficient mice. Science. 1996;274:795-798.
34. Cooper D, Lindberg FP, Gamble JR, Brown EJ, Vadas MA. The transendothelial migration of neutrophils involves integrin-associated protein (CD47). Proc Natl Acad Sci U S A. 1995;92:3978-3982.
35. Hagnerud S, Manna PP, Cella M, Stenberg A, Frazier WA, Colonna M, Oldenborg PA. Deficit of CD47 results in a defect of marginal zone DC, blunted immune response to particulate antigen and impairment of DC migration. J Immunol. 2006;176:5772-5778.
36. Avice M-N, Rubio M, Sergerie M, Delespesse G, Sarfati M. CD47 ligation selectively inhibits the development of human naïve T cells in to Th1 effectors. J Immunol. 2000;165:4624-4631.
37. Pettersen RD, Hestdal K, Olafsen MK, Lie SO, Lindberg FP. CD47 signals T cell death. J Immunol. 1999;162:7031-7040.
38. Manna PP, Dimitry J, Oldenborg PA, Frazier WA. CD47 Augments Fas/CD95-mediated Apoptosis. J Biol Chem. 2005;280:29637-29644.
39. Blazar BR, Lindberg FP, Ingulli E, Panoskaltsis-Mortari A, Oldenborg P-A, Iizuka K, Yokoyama WM, Taylor PA. CD47 (integrin-associated protein) engagement of dendritic cell and macrophage counterreceptors is required to prevent the clearance of donor lymphohematopoietic cells. J Exp Med. 2001;194:541-549.
40. Oldenborg P-A, Zheleznyak A, Fang Y-F, Lagenaur CF, Gresham HD, Lindberg FP. Role of CD47 as a marker of self on red blood cells. Science. 2000;288:2051-2054.
41. Oldenborg PA, Gresham HD, Lindberg FP. CD47-signal regulatory protein alpha (SIRPalpha) regulates Fcgamma and complement receptor-mediated phagocytosis. J Exp Med. 2001;193:855-862.
42. Ikeda H, Okazawa H, Ohnishi H, Murata Y, Oldenborg PA, Matozaki T. Mutational analysis of the mechanism of negative regulation by SRC homology 2 domain-containing protein tyrosine phosphatase substrate-1 of phagocytosis in macrophages. J Immunol. 2006;177:3123-3132.
43. Okazawa H, Motegi S-I, Ohyama N, Ohnishi H, Tomizawa T, Kaneko Y, Oldenborg P-A, Ishikawa O, Matozaki T. Negative regulation of phagocytosis in macrophages by the CD47-SHPS-1 system. J Immunol. 2005;174:2004-2011.
44. Wang H, VerHalen J, Madariaga ML, Xiang S, Wang S, Lan P, Oldenborg PA, Sykes M, Yang YG. Attenuation of phagocytosis of xenogeneic cells by manipulating CD47. Blood. 2007;109:836-842.
45. Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA, Bouck NP. A tumor supporessor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci U S A. 1990;87:6624-6628.
46. Weinstat-Saslow DL, Zabrenetzky VS, VanHoutte K, Frazier WA, Roberts DD, Steeg PS. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res. 1994;54:6504-6511.
47. Rodriguez-Manzaneque JC, Lane TF, Ortega MA, Hynes RO, Lawler J, Iruela-Arispe ML. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci U S A. 2001;98:12485-12490.
48. Ren B, Yee KO, Lawler J, Khosravi-Far R. Regulation of tumor angio-genesis by thrombospondin-1. Biochim Biophys Acta. 2006;1765:178-188.
49. Lawler J, Miao W-M, Duquette M, Bouck N, Bronson RT, Hynes RO. Thrombospondin-1 gene expression affects survival and tumor spectrum of p53-deficient mice. Am J Pathol. 2001;159:1949-1956.
50. Dawson DW, Pearce SF, Zhong R, Silverstein RL, Frazier WA, Bouck NP. CD36 mediates the inhibitory effects of thrombospondin on endothelial cells. J Cell Biol. 1997;138:707-717.
51. Cooke JP. NO and angiogenesis. Atheroscler Suppl. 2003;4:53-60.
52. Fukumura D, Gohongi T, Kadambi A, Izumi Y, Ang J, Yun CO, Buerk DG, Huang PL, Jain RK. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci U S A. 2001;98:2604-2609.
53. Ackah E, Yu J, Zoellner S, Iwakiri Y, Skurk C, Shibata R, Ouchi N, Easton RM, Galasso G, Birnbaum MJ, Walsh K, Sessa WC. Akt1/protein kinase Balpha is critical for ischemic and VEGF-mediated angiogenesis. J Clin Invest. 2005;115:2119-2127.
54. Morbidelli L, Donnini S, Ziche M. Role of nitric oxide in the modulation of angiogenesis. Curr Pharm Des. 2003;9:521-530.
55. Ridnour LA, Thomas DD, Donzelli S, Espey MG, Roberts DD, Wink DA, Isenberg JS. The biphasic nature of nitric oxide responses in tumor biology. Antioxid Redox Signal. 2006;8:1329-1337.
56. Isenberg JS, Ridnour LA, Perruccio EM, Espey MG, Wink DA, Roberts DD. Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner. Proc Natl Acad Sci U S A. 2005;102:13141-13146.
57. Isenberg JS, Ridnour LA, Dimitry J, Frazier WA, Wink DA, Roberts DD. CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1. J Biol Chem. 2006;281:26069-26080.
58. Isenberg JS, Romeo MJ, Yu C, Yu CK, Nghiem K, Monsale J, Rick ME, Wink DA, Frazier WA, Roberts DD. Thrombospondin-1 stimulates platelet aggregation by blocking the anti-thrombotic activity of nitric oxide/cGMP signaling. Blood. 2008;111:613-623.
59. Ignarro LJ, Cirino G, Casini A, Napoli C. Nitric oxide as a signaling molecule in the vascular system: an overview. J Cardiovasc Pharmacol. 1999;34:879-886.
60. Ignarro LJ. Nitric oxide as a unique signaling molecule in the vascular system: a historical overview. J Physiol Pharmacol. 2002;53:503-514.
61. Naseem KM. The role of nitric oxide in cardiovascular diseases. Mol Aspects Med. 2005;26:33-65.
62. Muto A, Fitzgerald TN, Pimiento JM, Maloney SP, Teso D, Paszkowiak JJ, Westvik TS, Kudo FA, Nishibe T, Dardik A. Smooth muscle cell signal transduction: Implications of vascular biology for vascular surgeons. J Vasc Surg. 2007;45 Suppl A:15-24.
63. Haga JH, Li YS, Chien S. Molecular basis of the effects of mechanical stretch on vascular smooth muscle cells. J Biomech. 2007;40:947-960.
64. Isenberg JS, Hyodo F, Matsumoto K, Romeo MJ, Abu-Asab M, Tsokos M, Kuppusamy P, Wink DA, Krishna MC, Roberts DD. Thrombospondin-1 limits ischemic tissue survival by inhibiting nitric oxide-mediated vascular smooth muscle relaxation. Blood. 2007;109:1945-1952.
65. Isenberg JS, Romeo MJ, Abu-Asab M, Tsokos M, Oldenborg A, Pappan L, Wink DA, Frazier WA, Roberts DD. Increasing survival of ischemic tissue by targeting CD47. Circ Res. 2007;100:712-720.
66. Isenberg JS PL, Romeo MJ, Abu-Asab M, Tsokos M, Wink DA, Frazier WA, Roberts DD. Blockade of thrombospndin-1-CD47 interactions prevents necrosis of full thickness skin grafts. Ann Surgery. 2008;247:180-190.
67. Isenberg JS, Hyodo F, Pappan LK, Abu-Asab M, Tsokos M, Krishna MC, Frazier WA, Roberts DD. Blocking thrombospondin-1/CD47 signaling alleviates deleterious effects of aging on tissue responses to ischemia. Arterioscler Thromb Vasc Biol. 2007;27:2582-2588.
68. Chalothorn D, Clayton JA, Zhang H, Pomp D, Faber JE. Collateral density, remodeling, and VEGF-A expression differ widely between mouse strains. Physiol Genomics. 2007;30:179-191.
69. Kopp HG, Hooper AT, Broekman MJ, Avecilla ST, Petit I, Luo M, Milde T, Ramos CA, Zhang F, Kopp T, Bornstein P, Jin DK, Marcus AJ, Rafii S. Thrombospondins deployed by thrombopoietic cells determine angiogenic switch and extent of revascularization. J Clin Invest. 2006;116:3277-3291.
70. Isenberg JS, Wink DA, Roberts DD. Thrombospondin-1 antagonizes nitric oxide-stimulated vascular smooth muscle cell responses. Cardiovasc Res. 2006;71:785-793.
71. Favier J, Germain S, Emmerich J, Corvol P, Gasc JM. Critical overexpression of thrombospondin 1 in chronic leg ischaemia. J Pathol. 2005;207:358-366.
72. Sezaki S, Hirohata S, Iwabu A, Nakamura K, Toeda K, Miyoshi T, Yamawaki H, Demircan K, Kusachi S, Shiratori Y, Ninomiya Y. Thrombospondin-1 is induced in rat myocardial infarction and its induction is accelerated by ischemia/reperfusion. Exp Biol Med (Maywood). 2005;230:621-630.
73. Thakar CV, Zahedi K, Revelo MP, Wang Z, Burnham CE, Barone S, Bevans S, Lentsch AB, Rabb H, Soleimani M. Identification of thrombospondin 1 (TSP-1) as a novel mediator of cell injury in kidney ischemia. J Clin Invest. 2005;115:3451-3459.
74. Distler JH, Jungel A, Pileckyte M, Zwerina J, Michel BA, Gay RE, Kowal-Bielecka O, Matucci-Cerinic M, Schett G, Marti HH, Gay S, Distler O. Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis. Arthritis Rheum. 2007;56:4203-4215.
75. Lin TN, Kim GM, Chen JJ, Cheung WM, He YY, Hsu CY. Differential regulation of thrombospondin-1 and thrombospondin-2 after focal cerebral ischemia/reperfusion. Stroke. 2003;34:177-186.
76. Yetik-Anacak G, Catravas JD. Nitric oxide and the endothelium: history and impact on cardiovascular disease. Vascul Pharmacol. 2006;45:268-276.
77. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome - a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006;23:469-480.
78. Biddinger SB, Almind K, Miyazaki M, Kokkotou E, Ntambi JM, Kahn CR. Effects of diet and genetic background on sterol regulatory element-binding protein-1c, stearoyl-CoA desaturase 1, and the development of the metabolic syndrome. Diabetes. 2005;54:1314-1323.
79. Cook S, Hugli O, Egli M, Vollenweider P, Burcelin R, Nicod P, Thorens B, Scherrer U. Clustering of cardiovascular risk factors mimicking the human metabolic syndrome X in eNOS null mice. Swiss Med Wkly. 2003;133:360-363.
80. Wang S, Shiva S, Poczatek MH, Darley-Usmar V, Murphy-Ullrich JE. Nitric oxide and cGMP-dependent protein kinase regulation of glucose-mediated thrombospondin 1-dependent transforming growth factor-beta activation in mesangial cells. J Biol Chem. 2002;277:9880-9888.
81. Danielewski O, Schultess J, Smolenski A. The NO/cGMP pathway inhibits Rap 1 activation in human platelets via cGMP-dependent protein kinase I. Thromb Haemost. 2005;93:319-325.
82. Dixit VM, Haverstick DM, O'Rourke KM, Hennessy SW, Grant GA, Santoro SA, Frazier WA. A monoclonal antibody against human thrombospondin inhibits platelet aggregation. Proc Natl Acad Sci U S A. 1985;82:3472-3476.
83. Leung LL. Role of thrombospondin in platelet aggregation. J Clin Invest. 1984;74:1764-1772.
84. Voit S, Udelhoven M, Lill G, Aktas B, Nieswandt B, Schror K, Weber AA. The C-terminal peptide of thrombospondin-1 stimulates distinct signaling pathways but induces an activation-independent agglutination of platelets and other cells. FEBS Lett. 2003;544:240-245.
85. Tulasne D, Judd BA, Johansen M, Asazuma N, Best D, Brown EJ, Kahn M, Koretzky GA, Watson SPC. terminal peptide of thrombospondin-1 induces platelet aggregation through the Fc receptor gamma -chain-associated signaling pathway and by agglutination. Blood. 2001;98:3346-3352.
86. Fitzpatrick DL OHD, Burnell AM. Multiple lineage specific expansions within the guanylyl cyclase gene family. BMC Evol Biol. 2006;6:26-43.
87. McKenzie P, Chadalavada SC, Bohrer J, Adams JC. Phylogenomic analysis of vertebrate thrombospondins reveals fish-specific paralogues, ancestral gene relationships and a tetrapod innovation. BMC Evol Biol. 2006;6:33.
88. Barbato JE, Tzeng E. Nitric oxide and arterial disease. J Vasc Surg. 2004;40:187-193.
89. Isenberg JS, Jia Y, Fukuyama J, Switzer CH, Wink DA, Roberts DD. Thrombospondin-1 inhibits nitric oxide signaling via CD36 by inhibiting myristic acid uptake. J Biol Chem. 2007;282:15404-15415.
90. Calzada MJ, Roberts DD. Novel integrin antagonists derived from thrombospondins. Curr Pharm Des. 2005;11:849-866.
91. Orr AW, Elzie CA, Kucik DF, Murphy-Ullrich JE. Thrombospondin signaling through the calreticulin/LDL receptor-related protein co-complex stimulates random and directed cell migration. J Cell Sci. 2003;116:2917-2927.
92. Calzada MJ, Annis DS, Zeng B, Marcinkiewicz C, Banas B, Lawler J, Mosher DF, Roberts DD. Identification of novel β1 integrin binding sites in the type 1 and type 2 repeats of thrombospondin-1. J Biol Chem. 2004;279:41734-41743.
93. Dixit VM, Galvin NJ, O'Rourke KM, Frazier WA. Monoclonal antibodies that recognize calcium-dependent structures of human thrombospondin. Characterization and mapping of their epitopes. J Biol Chem. 1986;261:1962-1968.
94. Kvansakul M, Adams JC, Hohenester E. Structure of a thrombospondin C-terminal fragment reveals a novel calcium core in the type 3 repeats. EMBO J. 2004;23:1223-1233.
95. Carlson CB, Bernstein DA, Annis DS, Misenheimer TM, Hanna BA, Mosher DF, Keck JL. Structure of the calcium-rich signature domain of human thrombospondin-2. Nat Struct Biol Mol Biol. 2005;12:910-914.